Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases;La terapia biologica con anti-TNFα nelle spondiloartriti e in altre malattie autoimmuni

Reumatismo

Volumn 57, Issue SUPPL. 4, 2005, Pages 22-29

  Lapadula, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Autoimmune diseases; Efficacy; TNF inhibitors; Tumor Necrosis Factor alfa

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT ONSET STILL DISEASE; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; BIOLOGICAL THERAPY; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; HUMAN; PSORIATIC ARTHRITIS; REVIEW;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; AUTOIMMUNE DISEASES; BEHCET SYNDROME; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SPONDYLARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 32644441346     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Toussirot E, Lafforgue P, Boucraut J, Despieds P, Schiano A, Bernard D, et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994; 13: 175-80.
2. Canete JD, Llena J, Collado A, Sanmarti R, Gaya A, Gratacos J, et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997; 36: 38-42.
3. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
4. Crew MD, Effros RB, Walford RL, Zeller E, Cheroutre H, Brahn E. Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. J Interferon Cytokine Res 1998; 18: 219-25.
5. Brandt J, Haibel H, Comely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-52.
6. Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 2001; 44: 2936-7.
7. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001; 28: 1605-14.
8. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
9. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33.
10. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64: 229-34.
11. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62: 1218-20.
12. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112-7.
13. Marzo-Ortega H, McGonagle D, Haugeberg G, Green MJ, Stewart SP, Emery P. Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Ann Rheum Dis 2003; 62: 1020-1.
14. Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-56.
15. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
16. Davis JC, Jr., van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
17. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-600.
18. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
19. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72.
20. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years. Clin Exp Rheumatol 2002; 20: 115.
21. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-9.
22. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De KF, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-65.
23. Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003; 49: 541-5.
24. Provenzano G, Termini A, Le MC, Rinaldi F. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. Ann Rheum Dis 2003; 62: 680-1.
25. Antoni C, Kavanaugh A, Kirkham B, Burmester G, Manger B, Tutuncu Z, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. EULAR 2003 Abstract.
26. Antoni C, Kavanaugh A, Kirkham B. The infliximab multinational Psoriatic arthritis controlled trial. Arthritis Rheum 2002; 46 (suppl. 985), S381.
27. Kavanaugh A, Krueger G, De Vlam, Birbara CA, Beutler A, Guzzo CA, et al. Infliximab significantly improves joint and skin involvment in psoriatic arthtritis to a substantial extent and irrespective of baseline joint involvment or MTX use: analysis of clinical response from the IMPACT2 trial. Arthritis Rheum 2004; 50 S617.
28. Van den Bosch F, Kruithof E, Baeten D, De KF, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428-33.
29. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002; 29: 118-22.
30. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004; 31: 531-8.
31. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62: 74-6.
32. Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003; 5: 501-5.
33. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-608.
34. Dechant C, Schauenberg P, Antoni CE, Kraetsch HG, Kalden JR, Manger B. [Longterm outcome of TNF blockade in adult-onset Still's disease]. Dtsch Med Wochenschr 2004; 129: 1308-12.
35. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001; 60 Suppl 3: iii55-iii57.
36. Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001; 19: 329-32.
37. Caramaschi P, Biasi D, Carletto A, Bambara LM. A case of adult onset Still's disease treated with infliximab. Clin Exp Rheumatol 2002; 20: 113.
38. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002; 46: 1171-6.
39. Falappone PC, Iannone F, Scioscia C, Grattagliano V, Covelli M, Lapadula G. [The treatment of recurrent uveitis with TNF-alpha inhibitors]. Reumatismo 2004; 56: 185-9.
40. Giansanti F, Barbera ML, Virgili G, Fieri B, Emmi L, Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur J Ophthalmol 2004; 14: 445-8.
41. Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 2004; 63: 744-5.
42. Mansour AM. Infliximab treatment of posterior uveitis. Ophthalmology 2004; 111: 197-8.
43. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362-8.
44. Sayarlioglu M, Cinal A, Topcu N, Demirok A. Effect of infliximab on refractory uveitis in Behcet's disease. Ann Pharmacother 2004; 38: 901-2.
45. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004; 140: 404-6.
46. Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, et al. Infliximab in refractory uveitis due to Behcet's disease. Clin 7).
47. Yucel AE, Kart-Koseoglu H, Akova YA, Demirhan B, Boyacioglu S. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease. Rheumatology (Oxford) 2004; 43: 394-6.
48. Gulli S, Arrigo C, Bocchino L, Morgante L, Sangari D, Castagna I, et al. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 2003; 4: 19.
49. Katsiari CG, Theodossiadis PG, Kaklamanis PG, Markomichelakis NN, Sfikakis PP. Successful long-term treatment of refractory Adamantiades-Behcet's disease (ABD) with infliximab: report of two patients. Adv Exp Med Biol 2003; 528: 551-5.
50. Kram MT, May LD, Goodman S, Molinas S. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003; 46: 118-21.
51. Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Ann Rheum Dis 2003; 62: 280-1.
52. Morris DS, Gavin MP, Sturrock RD. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behcet's disease. Adv Exp Med Biol 2003; 528: 557-9.
53. Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behcet's disease. Arthritis Rheum 2003; 49: 599-600.
54. Andreu M, Ramanoelina J, Fajnkuchen F, Mouthon L, Cohen P, Laroche L, et al. [Treatment of severe Behcet's disease with anti-TNF-alpha: infliximab. A case report]. Ann Med Interne (Paris) 2002; 153: 414-5.
55. Estrach C, Mpofu S, Moots RJ. Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002; 41: 1213-4.
56. Scheinberg MA. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol 2002; 20: 733-4.
57. Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002; 61 Suppl 2: ii51-ii53.
58. Triolo G, Vadala M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 2002; 61: 560-1.
59. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001; 120: 995-9.
60. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford) 2001; 40: 473-4.
61. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49: 725-28.